WTX-330 is a fusion protein commercialized by Werewolf Therapeutics, with a leading Phase I program in Non-Hodgkin Lymphoma. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of WTX-330’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for WTX-330 is expected to reach an annual total of $14 mn by 2039 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
WTX-330 is under development for the treatment of relapsed or refractory solid tumors, lymphoma, colon carcinoma, metastatic melanoma, breast cancer, metastatic hormone refractory (castration resistant, androgen-independent) prostate cancer, non-hodgkin lymphoma and unspecified B cell lymphoma. The drug candidate is a systemically delivered, conditionally activated interleukin-12 (IL-12) INDUKINE molecule, which acts by targeting interleukin 12 receptor (IL12R). It is being developed based on protein engineering technology (PREDATOR).
Werewolf Therapeutics Overview
Werewolf Therapeutics is a biopharmaceutical company that discovers and develops treatments for cancer. The company investigating WTX-124, a conditionally activated interleukin-2 (IL-2) based drug to treat multiple tumor types and WTX-330 and WTX-613 drugs administered as monotherapies for refractory and immunologically unresponsive tumors. Werewolf Therapeutics utilizes its proprietary Predator protein engineering technology platform to identify, design, optimize and validate immuno-oncology, autoimmune and inflammatory disease product candidates. It’s protein engineering technology integrates protein design elements to improve activity, stability and tumor selectivity within a single molecule. Werewolf Therapeutics is headquartered in Cambridge, Massachusetts, the US.
The company reported revenues of (US Dollars) US$16.4 million for the fiscal year ended December 2022 (FY2022). The operating loss of the company was US$56.1 million in FY2022, compared to an operating loss of US$50.1 million in FY2021. The net loss of the company was US$53.8 million in FY2022, compared to a net loss of US$50 million in FY2021.
For a complete picture of WTX-330’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.